Mayzent

Adult patients w/ secondary progressive multiple sclerosis w/ active disease evidenced by relapses or imaging features of inflammatory activity.

Initially 0.25 mg once daily in the morning on days 1 & 2, followed by 0.5 mg once daily in the morning on day 3, 0.75 mg once daily in the morning on day 4 & 1.25 mg once daily in the morning on day 5. Maintenance dose: 2 mg once daily. Patient w/ CYP2C9*2*3 or *1*3 genotype Maintenance dose: 1 mg once daily.

May be taken with or without food. Swallow whole w/ water.

Hypersensitivity to siponimod, peanut & soya. Immunodeficiency syndrome. History of progressive multifocal leukoencephalopathy or cryptococcal meningitis. Active malignancies. Patients who in the previous 6 mth had a MI, unstable angina pectoris, stroke/transient ischaemic attack, decompensated heart failure (requiring inpatient treatment) or NYHA class III/IV heart failure. Patients w/ history of 2nd-degree Mobitz type II AV block, 3rd-degree AV block, SA heart block or sick-sinus syndrome, if they do not wear a pacemaker. Patients homozygous for CYP2C9*3 (CYP2C9*3*3) genotype (poor metaboliser). Severe liver impairment (Child-Pugh class C). Women of childbearing potential not using effective contraception. Pregnancy.

Immunosuppressants

L04AE03 - siponimod ; Belongs to the class of sphingosine-1-phosphate (S1P) receptor modulators. Used as immunosuppressants.

POM